

<b>FEE TRANSMITTAL</b> <b>For FY 2005</b>  <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		<b>Complete if Known</b>		
		Application Number	10/758,335-Conf. #6410	
		Filing Date	January 15, 2004	
		First Named Inventor	Seth J. ORLOW	
		Examiner Name	J. D. Anderson	
TOTAL AMOUNT OF PAYMENT (\$)		180.00	Art Unit	1614
			Attorney Docket No.	71369.368US1/PFI-016CIPDIV

**METHOD OF PAYMENT** (check all that apply)

☐ Check   ☐ Credit Card   ☐ Money Order   ☐ None   ☐ Other (please identify): \_\_\_\_\_

☒ Deposit Account   Deposit Account Number: 08-0219   Deposit Account Name: Wilmer Cutler Pickering Hale and Dorr LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below   ☐ Charge fee(s) indicated below, **except for the filing fee**

☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17   ☒ Credit any overpayments

**FEE CALCULATION**

**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES**

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

**Total Claims**   **Extra Claims**   **Fee (\$)**   **Fee Paid (\$)**   **Multiple Dependent Claims**

\_\_\_\_\_ - 20 = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_   **Fee (\$)**   **Fee Paid (\$)**

HP = highest number of total claims paid for, if greater than 20.

**Indep. Claims**   **Extra Claims**   **Fee (\$)**   **Fee Paid (\$)**

\_\_\_\_\_ - 3 = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

HP = highest number of independent claims paid for, if greater than 3.

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____	_____	_____ / 50 (round up to a whole number) x _____	_____	_____

**4. OTHER FEE(S)**


	Fees Paid (\$)
Non-English Specification, \$130 fee (no small entity discount)	
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement	180.00

**SUBMITTED BY**

Signature	<i>Ann-Louise Kerner</i>	Registration No. (Attorney/Agent)	33,523	Telephone	(617) 526-6000
Name (Print/Type)	Ann-Louise Kerner, Ph.D.	Date	October 6, 2006		

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 6, 2006   Signature: *Rochelle Capobianco* (Rochelle Capobianco)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 6, 2006

Signature:

*Rochelle Capobianco*  
(Rochelle Capobianco)

Docket No.: 0071369.00368US1  
(PFI-016CIPDIV)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Seth J. ORLOW et al. Confirmation No.: 6410  
Application No.: 10/758,335 Art Unit: 1614  
Filed: January 15, 2004 Examiner: J. D. Anderson  
Title: METHODS AND COMPOSITIONS THAT AFFECT  
MELANOGENESIS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: October 6, 2006

10/12/2006 WASFAW1 00000111 080219 10758335  
01 FC:1806 180.00 DA

*Ann-Louise Kerner*  
Ann-Louise Kerner, Ph.D.  
Registration No.: 33,523  
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109  
(617) 526-6000 (telephone)  
(617) 526-5000 (facsimile)



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/758,335-Conf. #6410
				Filing Date	January 15, 2004
				First Named Inventor	Seth J. ORLOW
				Art Unit	1614
				Examiner Name	J. D. Anderson
Sheet	1	of	2	Attorney Docket Number	0071369.00368US1

#### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,628,987	05-13-1997	Fuller	
	AB	US-5,686,103	11-11-1997	Redziniak et al.	

#### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO-97/00892	01-09-1997	The Government of the United States of America, represented by The Secretary Department of Health and Human Services		
	BB	WO-01/01131	01-04-2001	Univ New York		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

#### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	ABDEL-MALEK, et al., "Mitogenic, Melanogenic and cAMP Responses of Cultured Neonatal Human Melanocytes to Commonly Used Mitogens", Journal of Cellular Physiology, 150:416-425 (1992)	
	CB	ANCANS, et al., "Activation of Melanogenesis by Vacuolar Type H <sup>+</sup> -ATPase Inhibitors in Amelanotic, Tyrosinase Positive Human and Mouse Melanoma Cells", FEBS Letters, 478:57-60 (2000)	
	CC	ANSEL, et al., <u>Pharmaceutical Dosage Forms and Drug Delivery Systems</u> , Sixth Ed., A Lea & Febiger Book, Williams & Wilkins, Baltimore (1995) (cover of book and page (i))	
	CD	BOUCHARD, et al., "Induction of Pigmentation in Mouse Fibroblasts by Expression of Human Tyrosinase cDNA", J. Exp. Med., 169:2029-2042 (1989)	
	CE	BRILLIANT, et al., "Anatomy of Pigment Cell Genes Acting at the Cellular Lever", in <u>The Pigmentary System: Physiology and Pathophysiology</u> , Norlund, et al., eds., Oxford University Press, Chapter 18, pp. 217-229 (1998)	
	CF	CHAKRABORTY, et al., "Effect of Arbutin on Melanogenic Proteins in Human Melanocytes", Pigment Cell Research, 11:206-212 (1998)	
	CG	GARDNER, et al., "The Complete Nucleotide Sequence of an Infectious Clone of Cauliflower Mosaic Virus by M13mp7 Shotgun Sequencing", Nucleic Acids Research, 9(12):2871-2888 (1981)	
	CH	GILBERT, et al., "Useful Proteins from Recombinant Bacteria", Sci. Am., 242(4):74-94 (1980)	
	CI	HARLOW, et al., <u>Antibodies - A Laboratory Manual</u> , Cold Spring Harbor Laboratory (1988) (cover of book and page (i))	
	CJ	HU, et al., "Regulation of Melanogenesis by Human Uveal Melanocytes In Vitro", Exp. Eye	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/758,335-Conf. #6410
				Filing Date	January 15, 2004
				First Named Inventor	Seth J. ORLOW
				Art Unit	1614
				Examiner Name	J. D. Anderson
Sheet	2	of	2	Attorney Docket Number	0071369.00368US1
			Res., 64:397-404 (1997)		
	CK		IMOKAWA, et al., "Skin Organ Culture Model for Examining Epidermal Melanization", Journal of Investigative Dermatology, 100:47-54 (1993)		
	CL		JIMENEZ, et al., "Tyrosinases from Two Different Loci are Expressed by Normal and by Transformed Melanocytes", Journal of Biological Chemistry, 266(2):1147-1156 (1991)		
	CM		KUZUMAKI, et al., "Eumelanin Biosynthesis is Regulated by Coordinate Expression of Tyrosinase and Tyrosinase-Related Protein-1 Genes", Experimental Cell Research, 207:33-40 (1993)		
	CN		LERNER, et al., "Biochemistry of Melanin Formation", Physiol. Rev., 30(1):91-126 (1950)		
	CO		MACDONALD, "Expression of the Pancreatic Elastase I Gene in Transgenic Mice", Hepatology, 7(1):42S-51S (1987)		
	CP		MASON, et al., "The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy", Science, 234(4782):1372-1378 (1986)		
	CQ		NIEKRASZ, et al., "The Pig as Organ Donor for Man", Transplantation Proceedings, 24(2):625-626 (1992)		
	CR		OETTING, et al., "Mutations of the Human P Gene Associated with Type II Oculocutaneous Albinism (OCA2)", Human Mutation, 12(6):433-434 (1998) (abstract only)		
	CS		ORLOW, et al., "Retinoic Acid is a Potent Inhibitor of Inducible Pigmentation in Murine and Hamster Melanoma Cell Lines", Journal of Investigative Dermatology, 64(4):461-464 (1990)		
	CT		ORLOW, "The Biogenesis of Melanosomes", in <i>The Pigmentary System: Physiology and Pathophysiology</i> , Norlund, et al., eds, Oxford University Press, Chapter 6, pp. 97-106 (1998)		
	CU		ORNITZ, et al., "Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice", Cold Spring Harb. Symp. Quant. Biol., 50:399-409 (1985)		
	CV		PINKERT, et al., "An Albumin Enhancer Located 10 kb Upstream Functions Along with its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice", Genes & Development, 1:268-276 (1987)		
	CW		Product Information Sigma: Composition of the Medium MCDB-153		
	CX		Product Information Sigma: Composition of the Medium Ham's F10		
	CY		Remington's Pharmaceutical Sciences, 18th Edition, Alfonso Gennaro, Editor, Mack Publishing Company, Easton, PA (1990)		
	CZ		SAKAI, et al., "Modulation of Murine Melanocyte Function <i>in vitro</i> by Agouti Signal Protein", EMBO Journal, 16(12):3544-3552 (1997)		
	CA1		SCHWARTZ, et al., <i>Surface Active Agents, Their Chemistry and Technology</i> , Interscience Publishers, Inc, New York, NY (1949)		
	CB1		SEIBERG, et al., "Inhibition of Melanosome Transfer Results in Skin Lightening", J. Invest. Dermatol., 115:162-167 (2000)		
	CC1		SEIJI, et al., "Subcellular Localization of Melanin Biosynthesis", Annals NY Acad. Sci., 100:497-533 (1963)		
	CD1		SHANI, "Tissue-Specific Expression of Rat Myosin Light-Chain 2 Gene in Transgenic Mice", Nature, 314:283-286 (1985)		
	CE1		VIRADOR, et al., "A Standardized Protocol for Assessing Regulators of Pigmentation", Analytical Biochemistry, 270:207-219 (1999)		
	CF1		YOKOYAMA, et al., "Conserved Cysteine to Serine Mutation in Tyrosinase is RESPONSIBLE for the Classical Albino Mutation in Laboratory Mice", Nucleic Acids Research, 18(24):7293-7298 (1990)		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p><sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.</p>					